Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet

• ClinicalTrials.gov Identifier: NCT02383511
• Recruitment Status: Completed
• First Posted: March 9, 2015
• Last Update Posted: August 26, 2015
• Sponsor: Summit Therapeutics
• Information provided by (Responsible Party): Summit Therapeutics

Study Description

Brief Summary:

Placebo-controlled, multi-centre, randomized, double-blind dose escalation study. The aim is to evaluate the pharmacokinetics (PK) and safety of SMT C1100 in paediatric patients with Duchenne Muscular Dystrophy (DMD) who follow a balanced diet.

Condition or disease	Intervention/treatment	Phase
Muscular Dystrophy, Duchenne	Drug: SMT C1100	Phase 1

Detailed Description:

Primary Objective:

To determine the plasma concentration of SMT C1100 calculated at each time point for each subject (sample size (n), mean, standard deviation (SD), percentage of coefficient of variation (%CV), geometric mean, median, minimum, and maximum for the parent and the major metabolites).

Secondary Objectives:

1. To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD) by assessing the participants adverse events, ECG results, vital signs and laboratory tests.
2. To evaluate the diurnal variability in the steady state PK of SMT C1100 calculated at each time point for each subject (sample size (n), mean, standard deviation (SD), percentage of coefficient of variation (%CV), geometric mean, median, minimum, and maximum for the parent and the major metabolites).
3. To evaluate reductions in creatine phosphokinase as a potential pharmacodynamic (PD) marker of SMT C1100 activity and clinical benefit.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 12 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 1b Placebo-controlled, Multi-centre, Randomized, Double-blind Dose Escalation Study to Evaluate the Pharmacokinetics (PK) and Safety of SMT C1100 in Patients With Duchenne Muscular Dystrophy (DMD) Who Follow a Balanced Diet
• Study Start Date: February 2015
• Actual Primary Completion Date: August 2015
• Actual Study Completion Date: August 2015

Arms and Interventions

Arm	Intervention/treatment
Sequence 1; Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)	Drug: SMT C1100; Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
Sequence 2; Drug: SMT C1100 or placebo 3-treatment (Period 1,2, and 3)	Drug: SMT C1100; Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
Sequence 3; Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)	Drug: SMT C1100; Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID

Outcome Measures

Primary Outcome Measures :

1. Pharmacokinetic parameters at different dose levels of SMT C1100 [ Time Frame: 28 days ]
   To determine the plasma concentration of SMT C1100 parent and the major metabolites calculated at each time point for each subject.

Secondary Outcome Measures :

1. Safety and tolerability of SMT C1100 [ Time Frame: 28 days ]
   To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD) by assessing the participants adverse events.
2. Evaluation of plasma CK levels [ Time Frame: 42 days ]
   To evaluate reductions in plasma creatine phosphokinase as a potential pharmacodynamic (PD) marker of SMT C1100 activity and muscle benefit.
3. Pharmacokinetic parameters at different dose levels of SMT C1100 [ Time Frame: 28 Days ]
   To determine the plasma concentration of SMT C1100 major metabolites calculated at each time point for each subject.
4. Safety and tolerability of SMT C1100 [ Time Frame: 28 Days ]
   To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD) composite assessment of the participant's ECG results and laboratory tests.
5. Pharmacokinetic parameters at different dose levels of SMT C1100 [ Time Frame: 28 Days ]
   To evaluate the diurnal variability in the steady state PK of SMT C1100 calculated at each time point for each subject.

Eligibility Criteria

• Ages Eligible for Study: 5 Years to 13 Years (Child)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patients will be males of any ethnic origin with a genetic diagnosis of DMD.
2. Children between 5 and 13 years of age.
3. A parent/legal guardian must date and sign a written consent on behalf of the patient, according to International Conference on Harmonisation (ICH) and local regulations. This person must understand the contents of the consent, requirements of the study and have had an opportunity to review questions with a medically trained member of the site study team.
4. The patient is willing to give verbal or written age appropriate assent to participate.
5. For safety reasons, the patient's parent/legal guardian must have a good understanding of the English language, which the consent/assent forms are available, and understand the requirements for reporting of any AE to the Investigator.
6. The patient has 6 months or more stable systemic (Patients using an intermittent regimen of steroid are allowed to be enrolled) corticosteroid therapy prior to Screening. Dose modifications for body weight are permitted.
7. The patient or parent is willing to adhere to a balanced diet from 1 week prior to dosing until the end of the follow-up period.
8. Patients must agree to not have sexual intercourse during the study treatment phases and until the end of their participation in the study.

Exclusion Criteria:

1. Enrolment or participation in any therapeutic clinical trial within the prior 3 months or 5 times the half-life (whichever is longer). Prior exposure to SMT C1100 is NOT an exclusion criterion.
2. Known hypersensitivity to the excipients of the study drug or a previous history of drug allergy.
3. The patient or parent is unwilling to adhere to a balanced diet from 1 week prior to dosing until the end of the follow-up period.
4. Is dairy or lactose intolerant, has an allergy to egg or nuts or any other dietary restrictions that might interfere with the conduct of the study.
5. Is unable to refrain from eating cruciferous vegetables and barbecued (chargrilled) meat for the duration of the study.
6. Use of prohibited medication within 5 half-lives prior to baseline assessments, unless otherwise stated in protocol.
7. Need for mechanical ventilation.
8. The patient experiences intermittent or continuous difficulties in swallowing.
9. Non ambulatory.
10. Any clinically significant acute illness within 4 weeks of the start of dose administration.
11. Any comorbidity that, in the opinion of the Investigator, increases the risk of participating in the study.
12. Symptomatic cardiomyopathy that in the opinion of the Investigator prohibits participation in this study.
13. Abnormality in the 12-lead ECG at the Screening visit that, in the opinion of the Investigator, increases the risk of participating in the study.
14. Any clinically significant medical condition, other than DMD that in the opinion of the Investigator may increase the risk of participating in the study or interfere with the interpretation of safety or efficacy evaluations (e.g., concomitant illness, severe reflux, psychiatric condition or behavioural disorder).
15. The Patient smokes or has exposure to daily passive smoking (including parent/legal guardian, siblings) so as to minimise environmental factors causing CYP 1A induction.
16. Excessive exercise (Investigator opinion).

Contacts and Locations

Locations

United Kingdom

Heart of England NHS Foundation Trust - Heart Lands Hospital

Birmingham, United Kingdom, B9 5SS

Alder Hey Children's NHS Foundation Trust

Liverpool, United Kingdom, L12 2AP

Great Ormond Street Hospital for Children NHS Foundation Trust

London, United Kingdom, WC1N 3JH

Central Manchester University Hospitals NHS Foundation Trust- Royal Manchester Children's Hospital

Manchester, United Kingdom

Sponsors and Collaborators

Summit Therapeutics

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ricotti V, Spinty S, Roper H, Hughes I, Tejura B, Robinson N, Layton G, Davies K, Muntoni F, Tinsley J. Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy. PLoS One. 2016 Apr 7;11(4):e0152840. doi: 10.1371/journal.pone.0152840. eCollection 2016.

• Responsible Party: Summit Therapeutics
• ClinicalTrials.gov Identifier: NCT02383511
• Other Study ID Numbers: SMT C11003
• First Posted: March 9, 2015
• Last Update Posted: August 26, 2015
• Last Verified: August 2015

Additional relevant MeSH terms:

Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked